A Small Biotech Shows Competitive Potential Against AbbVie's Key Drug

Oruka Therapeutics is developing a drug that may outperform AbbVie’s Skyrizi in treating plaque psoriasis. Despite this potential competition, AbbVie reported strong Q1 results with $15 billion in revenue and rising stock prices.

By Prosper Junior Bakiny · Motley Fool · May 11, 2026, 21:15 UTC

Tickers: $ABBV $ORKA

Topics: AbbVie drug competition market share Oruka Therapeutics Skyrizi

Read the full article at Motley Fool

More World news

Joe Lavis Named to D CEO's 2027 Dallas 500 List PR Newswire · November 12, 2026, 16:26 UTC
Sanmina Corporation (SANM) Shares Rise 8% Amid Five-Day Winning Streak Seeking Alpha · November 12, 2026, 16:23 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal and National Security Concerns Motley Fool · November 12, 2026, 16:17 UTC
Citigroup Lowers Nvidia Price Target Following Jensen Huang's Departure Motley Fool · November 12, 2026, 16:19 UTC
The General Insurance and WWE Partner with Second Harvest Food Bank to Combat Food Insecurity in Nashville PR Newswire · November 12, 2026, 16:21 UTC
Fennec Pharmaceuticals Reports Record Q3 2026 Results with Significant EBITDA Growth Motley Fool · November 12, 2026, 16:11 UTC
Rockwell Medical Reports Q3 2026 Results and Announces Vantive Limited Acquisition Motley Fool · November 12, 2026, 16:11 UTC
BioHarvest Sciences Reports Q3 2026 Financial Results Amid Strategic Shift to Fragrance Development Motley Fool · November 12, 2026, 16:11 UTC
Xunlei Reports Q3 2026 Revenue Growth Amid Increased Operating Losses and Investment Adjustments Motley Fool · November 12, 2026, 16:11 UTC
Sandisk Shares Decline Following Resignation of Nvidia CEO Jensen Huang Motley Fool · November 12, 2026, 16:14 UTC